# Phase 2 overweight trials recruiting: 56 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 56 trials in phase 2 for overweight that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 overweight trials: 56 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/overweight

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 56
- Recruiting or not yet: 56
- Read on: November 19, 2026

## Trials

The 25 newest of 56, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946796 | Semaglutide Effects on Sperm Concentration in Overweight Infertile Men | Copenhagen University Hospital at Herlev | Phase 2 | Not yet recruiting | Infertility in Overweight Men | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946796) |
| November 10, 2026 | NCT07929298 | A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | Hangzhou Sciwind Biosciences Co., Ltd. | Phase 2 | Not yet recruiting | Overweight , Obesity, Weight Management | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929298) |
| November 5, 2026 | NCT07918625 | A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes | BrightGene Bio-Medical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obese Participants Without Diabetes | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918625) |
| October 29, 2026 | NCT07902752 | Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs | George Washington University | Phase 2 | Not yet recruiting | Obesity & Overweight, Respiratory Depression, Intranasal Drug Administration, Oxytocin, Bariatric Surgery | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902752) |
| October 22, 2026 | NCT07890376 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | Eli Lilly and Company | Phase 2 | Not yet recruiting | Obesity, Overweight | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890376) |
| October 20, 2026 | NCT07884058 | IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity | University of Yaounde 1 | Phase 2 | Not yet recruiting | Obesity & Overweight | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884058) |
| October 20, 2026 | NCT07882654 | A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN... | EktaH | Phase 2 | Not yet recruiting | Obesity / Overweight, Obesity (BMI Equal to or \>30) | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882654) |
| October 15, 2026 | NCT07874828 | PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Sarcoma,Soft Tissue | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874828) |
| October 5, 2026 | NCT07857473 | A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants | Immunwork, Inc. | Phase 2 | Not yet recruiting | Overweight and Obesity | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857473) |
| September 24, 2026 | NCT07837973 | Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | Alveus Therapeutics, Inc. | Phase 2 | Recruiting | Overweight , Obesity, Adults | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837973) |
| September 21, 2026 | NCT07830329 | Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or... | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Hidradenitis Suppurativa | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830329) |
| September 16, 2026 | NCT07823452 | Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity | Indiana University | Phase 2 | Not yet recruiting | Obesity & Overweight | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823452) |
| September 15, 2026 | NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | The Methodist Hospital Research Institute | Phase 2 | Not yet recruiting | Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820358) |
| September 4, 2026 | NCT07803991 | Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes. | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obesity | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803991) |
| August 24, 2026 | NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer | Tongji Hospital | Phase 2 | Not yet recruiting | Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I, Endometrioid Endometrial Cancer | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781150) |
| August 10, 2026 | NCT07754045 | Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults | Lumos Pharma | Phase 2 | Not yet recruiting | Obesity & Overweight | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754045) |
| August 7, 2026 | NCT07752979 | Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities | AbbVie | Phase 2 | Recruiting | Obesity, Overweight | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752979) |
| August 5, 2026 | NCT07747805 | GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD | The Cleveland Clinic | Phase 2 | Not yet recruiting | COPD, Obesity & Overweight, Sarcopenia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747805) |
| July 8, 2026 | NCT07690826 | A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obesity | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690826) |
| July 6, 2026 | NCT07685808 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Overweight or Obesity | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685808) |
| June 22, 2026 | NCT07658560 | A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes | BrightGene Bio-Medical Technology Co., Ltd. | Phase 2 | Recruiting | Overweight or Obese Participants Without Diabetes | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658560) |
| May 28, 2026 | NCT07612527 | Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation | Cairo University | Phase 2 | Recruiting | Obesity & Overweight, Bariatric Endoscopy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612527) |
| May 15, 2026 | NCT07589686 | A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight | Hoffmann-La Roche | Phase 2 | Not yet recruiting | Obesity or Overweight | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589686) |
| May 15, 2026 | NCT07589608 | A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or... | Eli Lilly and Company | Phase 2 | Recruiting | Overweight, Obesity | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589608) |
| May 8, 2026 | NCT07575438 | Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults | Sponsor not shown (see the record) | Phase 2 | Recruiting | Type 2 Diabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Prediabetes / Type 2 Diabetes, Obesity &... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575438) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 4 |
| Johns Hopkins University | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| BrightGene Bio-Medical Technology Co., Ltd. | 2 |
| Biomed Industries, Inc. | 1 |
| Indiana University | 1 |
| Cairo University | 1 |
| NeuroBiogen Co., Ltd | 1 |
| The Methodist Hospital Research Institute | 1 |
| University of Missouri, Kansas City | 1 |
| Medical College of Wisconsin | 1 |
| St. James's Hospital, Ireland | 1 |
| [AB Biotics, SA](https://specstream.ai/data/clinical-trials/company/ab-biotics-sa) | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| Hangzhou Sciwind Biosciences Co., Ltd. | 1 |
| Lumos Pharma | 1 |
| Wake Forest University | 1 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 1 |
| Copenhagen University Hospital at Herlev | 1 |
| Empros Pharma AB | 1 |
| Hudson Biotech | 1 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 1 |
| South West Sydney Local Health District | 1 |
| University of Southern California | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 28 |
| China | 9 |
| Australia | 3 |
| Canada | 3 |
| Egypt | 2 |
| Spain | 2 |
| Puerto Rico | 2 |
| Argentina | 2 |
| New Zealand | 1 |
| South Korea | 1 |
| Denmark | 1 |
| Germany | 1 |
| Poland | 1 |
| United Kingdom | 1 |
| Tunisia | 1 |
| France | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [Cancer treatment centers in the United States](https://specstream.ai/data/businesses/cancer-treatment-centers/united-states)
- [Artificial turf companies in the United States](https://specstream.ai/data/businesses/artificial-turf-companies/united-states)
- [Traffic ticketing law firms in the United States](https://specstream.ai/data/businesses/traffic-ticketing-law-firms/united-states)
- [Rehabilitation centers in the United States](https://specstream.ai/data/businesses/rehabilitation-centers/united-states)
- [Ophthalmology practices in the United States](https://specstream.ai/data/businesses/ophthalmology-practices/united-states)
